文献速递心力衰竭与心肌病心律失常

非缺血性心肌病中LVEF与心肌瘢痕对长期死亡风险及死亡模式的关联

Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy.
PubMed 文献 · Circulation · 2021-01-22

该前瞻性纵向结局注册研究纳入1020例接受心血管磁共振评估LVEF和瘢痕的非缺血性心肌病患者,中位随访5.2年。结果显示LVEF≤35%和瘢痕均与全因死亡和心源性死亡相关,但仅瘢痕与心脏性猝死(SCD)显著相关,且瘢痕范围对SCD等终点有显著增量预后价值,LVEF无增量预后价值。

要点

  • LVEF≤35%与全因死亡和心源性死亡相关,但与SCD风险无显著关联。
  • 心肌瘢痕与全因死亡、心源性死亡及SCD均强相关,且提供增量预后价值。
  • 瘢痕评估应纳入ICD一级预防的患者选择标准。

核心结论

  • 在非缺血性心肌病患者中,心肌瘢痕和LVEF均为全因死亡和心源性死亡的风险标志物,但瘢痕对SCD风险分层具有强且增量的预后价值,而LVEF无增量预后价值。

研究设计与样本

  • 前瞻性纵向结局注册研究,纳入1020例连续的非缺血性心肌病患者,在3个中心接受临床心血管磁共振成像以评估LVEF和瘢痕。

主要发现

  • 中位随访5.2年(四分位距3.8-6.6年),277例(27%)患者死亡。
  • LVEF≤35%和瘢痕均与全因死亡(log-rank检验P=0.002和P<0.001)及心源性死亡(P=0.001和P<0.001)显著相关。
  • 瘢痕与心脏性猝死(SCD)显著相关(P=0.001),而LVEF≤35%与SCD风险无显著关联(P=0.57)。
  • 多变量分析中,LVEF和瘢痕均为全因死亡和心源性死亡的独立风险标志物。
  • LVEF对全因死亡和心源性死亡的C统计量判别改善不显著,对SCD无增量预后价值;瘢痕范围对全部3个终点均显示显著增量预后价值和判别改善。

临床怎么用

  • 在非缺血性心肌病患者中,应考虑将心肌瘢痕评估纳入ICD一级预防的患者选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonischemic cardiomyopathy is a leading cause of reduced left ventricular ejection fraction (LVEF) and is associated with high mortality risk from progressive heart failure and arrhythmias. Myocardial scar on cardiovascular magnetic resonance imaging is increasingly recognized as a risk marker for adverse outcomes; however, left ventricular dysfunction remains the basis for determining a patient's eligibility for primary prophylaxis with implantable cardioverter-defibrillator. We investigated the relationship of LVEF and scar with long-term mortality and mode of death in a large cohort of patients with nonischemic cardiomyopathy. METHODS: This study is a prospective, longitudinal outcomes registry of 1020 consecutive patients with nonischemic cardiomyopathy who underwent clinical cardiovascular magnetic resonance imaging for the assessment of LVEF and scar at 3 centers. RESULTS: During a median follow-up of 5.2 (interquartile range, 3.8, 6.6) years, 277 (27%) patients died. On survival analysis, LVEF ≤35% and scar were strongly associated with all-cause (log-rank test P=0.002 and P<0.001, respectively) and cardiac death (P=0.001 and P<0.001, respectively). Whereas scar was strongly related to sudden cardiac death (SCD; P=0.001), there was no significant association between LVEF ≤35% and SCD risk (P=0.57). On multivariable analysis including established clinical factors, LVEF and scar are independent risk markers of all-cause and cardiac death. The addition of LVEF provided incremental prognostic value but insignificant discrimination improvement by C-statistic for all-cause and cardiac death, but no incremental prognostic value for SCD. Conversely, scar extent demonstrated significant incremental prognostic value and discrimination improvement for all 3 end points. On net reclassification analysis, the addition of LVEF resulted in no significant improvement for all-cause death (11.0%; 95% CI, -6.2% to 25.9%), cardiac death (9.8%; 95% CI, -5.7% to 29.3%), or SCD (7.5%; 95% CI, -41.2% to 42.9%). Conversely, the addition of scar extent resulted in significant reclassification improvement of 25.5% (95% CI, 11.7% to 41.0%) for all-cause death, 27.0% (95% CI, 11.6% to 45.2%) for cardiac death, and 40.6% (95% CI, 10.5% to 71.8%) for SCD. CONCLUSIONS: Myocardial scar and LVEF are both risk markers for all-cause and cardiac death in patients with nonischemic cardiomyopathy. However, whereas myocardial scar has strong and incremental prognostic value for SCD risk stratification, LVEF has no incremental prognostic value over clinical measures. Scar assessment should be incorporated into patient selection criteria for primary prevention implantable cardioverter-defibrillator placement.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Klem I, Klein M, Khan M, et al. Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy. Circulation. 2021. PMID: 33478245. doi:10.1161/CIRCULATIONAHA.120.048477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。